BRIEF-Genentech Phase III IMblaze370 Study Did Not Meet Primary Endpoint Compared To Regorafenib

* GENENTECH PROVIDES UPDATE ON PHASE III STUDY OF TECENTRIQ (ATEZOLIZUMAB) AND COTELLIC (COBIMETINIB) IN PEOPLE WITH HEAVILY PRE-TREATED LOCALLY ADVANCED OR METASTATIC COLORECTAL CANCER